Metabolic Endocrinology Type II Diabetes

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Type II Diabetes Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Type II Diabetes Projects
--AstraZeneca Plc
--Amgen Inc
--ConjuChem Inc.
--Bristol-Myers Squibb Company
--Eli Lilly & Co
--DiaMedica Inc.
--GlaxoSmithKline plc
--Genfit
--Kissei Pharmaceutical Co., Ltd.
--Johnson & Johnson
--Mitsubishi Tanabe Pharma Corporation
--Metabolex, Inc.
--Novo-Nordisk A/S
--Novartis AG
--Pfizer Inc
--Ortho-McNeil, Inc.
--Sanofi-Aventis
--Roche Holdings Ltd
--Teva Pharmaceutical Industries Ltd
--Takeda Pharmaceutical Company Limited

--Top Companies in early stage Type II Diabetes Projects
--Allergan Inc
--Akesis Pharmaceuticals Inc
--Arisaph Pharmaceuticals, Inc.
--Amgen Inc
--Bristol-Myers Squibb Company
--Biovitrum AB
--Diabetology Ltd
--DARA BioSciences, Inc.
--Eli Lilly & Co
--DiaKine Therapeutics, Inc.
--Incyte Corporation
--Genzyme Corporation
--Pfizer Inc
--Innodia Inc.
--Roche Holdings Ltd
--Protemix Corporation Limited
--SCOLR Pharma Inc
--Sanofi-Aventis
--TransTech Pharma, Inc.
--Theracos, Inc.

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Approved Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View